ESLA logo

ESTRELLA IMMUNOPHARMA INC

ESLANASDAQ
🏆 #4368 by market capUS Equity
$0.85▼ $0.01 (−1.20%)
Latest quote
🔔
Track ESLA
Get earnings, price moves & breaking news on Telegram
Track
24h▼ 1.2%
7d▲ 15.1%
14d▲ 57.7%
30d▲ 84.7%
ytd▼ 44.8%
1y▼ 65.3%
🏦Market Cap
$37M
Small Cap
📈Revenue Growth (YoY)
0.0%
Slowing
📊Gross Margin
0.0%
Thin
💵FCF Margin
0.0%
Thin
⚖️P/S Ratio
0.0x
Cheap
Otter Score
—
Insufficient data

Trading Snapshot

Day Range
$0.77 – $0.93
52-Week Range
$0.24 – $3.15
Volume (shares)
5,902
Avg Volume (shares)
—
Shares Outstanding
43.5M
Next Earnings
—

Fundamentals Snapshot

Annual Revenue
—
Last Q Revenue
—
P/E Ratio
-3.8
P/S Ratio
0.0x
EPS (TTM)
$-0.23
Dividend Yield
0.00%
Dilution (1yr)
+3.5%
ESLA logo

ESTRELLA IMMUNOPHARMA INC

ESLA
Financial Trends
RevenueThe total money the company brought in from sales, before subtracting any costs.
$0▲ +0.0% YoY
Operating IncomeProfit from the core business after operating costs, but before interest and taxes. Negative means the core business isn’t profitable yet.
−$13M▲ +47.7% YoY
Free Cash FlowCash left over after running the business and paying for equipment/capex. Negative means the company is burning cash.
−$2M▼ −42.6% YoY
Shares OutstandingHow many shares exist. Rising means the company is issuing more shares, which dilutes (shrinks) each existing owner’s slice.
38.0M▲ +3.5% YoY
Net CashCash minus total debt. Positive = more cash than debt (financially strong); negative = more debt than cash (net debt).
$1M▲ +$467K YoY
StockOtter · stockotter.space

About ESTRELLA IMMUNOPHARMA INC

Estrella Immunopharma, Inc. is an early-stage biopharmaceutical enterprise focused on creating T-cell therapies for various blood cancers and solid tumors, with its primary activities centered in the United States. The company's lead investigational drugs include EB103, which is in preclinical development for diffuse large B-cell lymphoma, and EB104, intended for the treatment of both diffuse large B-cell lymphoma and acute lymphocytic leukemia. Estrella also maintains a collaborative agreement with Imugene Limited, working together to develop solid tumor therapies that integrate Imugene's CF33-CD19t product candidate with Estrella's EB103. The company is based in Emeryville, California.

🦦

Otter Score Breakdown

How it's scoredFive components, each rated 1–5★ and equally weighted (20%), averaged to a 0–100 score:💎 Quality — gross margin🚀 Growth — revenue YoY⚖️ Valuation — P/S ratio⚡ Momentum — 30-day price change💧 Dilution — 1-yr share issuance (buybacks score higher)

Insufficient data for all five components.

💎Quality★★★★★
🚀Growth★★★★★
⚖️Valuation★★★★★
💧Dilution★★★★★
Overall Score
Insufficient data
—/100
Analyst data unavailable.

Latest News & Updates

News unavailable.